{"product_id":"cloverhealth-swot-analysis","title":"Clover Health SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Company’s Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eClover Health’s tech-driven Medicare Advantage model combines strong data analytics and value-based care partnerships with regulatory and margin pressures that warrant scrutiny; growth hinges on enrollment expansion and prudent cost control.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Clover Assistant Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe proprietary Clover Assistant gives Clover Health a clear edge by delivering real-time, data-driven care prompts to PCPs at the point of care, reducing missed interventions; in 2024 Clover reported a 12% relative rise in preventive care adherence where the Assistant was active. It ingests claims, EHR, and social determinants to flag gaps and suggest evidence-based actions, improving outcomes and helping lower long-term medical cost trends—Clover cites a 4–6% reduction in annual per-member medical spend in pilot cohorts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproving Medical Loss Ratio Performance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClover Health has cut its Medical Loss Ratio (MLR) toward the Medicare Advantage target, reporting a 2024 MLR improvement to ~88% from 92% in 2022 by reducing avoidable admissions and improving chronic care via its data platform; this drove a 2024 Medicare segment operating margin improvement to about 3% and supports pricing competitive premiums while aiming for 85% MLR or lower.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Transition to SaaS Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe launch and expansion of Counterpart Health lets Clover Health sell its care-management tech as a third-party SaaS product, opening a higher-margin revenue stream; in 2024 SaaS gross margins in health tech averaged ~70%, compared with ~8–12% underwriting margins in Medicare Advantage, so this shift can materially boost profitability. By 2025 Clover aims to grow Counterpart to serve 200+ partners, diversifying away from underwriting and lowering exposure to medical cost variability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Underserved Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpclover health carved a niche serving underserved medicare advantage populations often missed by big insurers as of they reported members with higher retention in core markets where social-determinants programs reduced er use pilot sites.\u003e\n\u003cptheir care model targets health equity and social determinants food transport boosting community ties brand loyalty growth in targeted counties outpaced system ma by percentage points\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e265,000 Medicare Advantage members (2025)\u003c\/li\u003e\n\u003cli\u003e12% ER use drop in pilot SDOH programs\u003c\/li\u003e\n\u003cli\u003eTargeted-county growth +4 pp vs national MA in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/pclover\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Liquidity and Capital Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas of late clover health holds about million in cash and short-term investments giving it enough runway to fund growth ai r without near-term external financing pressure.\u003e\n\u003cpthis liquidity cushions the company against medical-claims volatility and regulatory shifts supports planned investments in ai-driven care management tied to rollout targets.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$420M cash \u0026amp; short-term investments (late 2025)\u003c\/li\u003e\n\u003cli\u003eNo imminent debt maturities forcing capital raise\u003c\/li\u003e\n\u003cli\u003eFunds allocated to AI R\u0026amp;D and 2026 rollouts\u003c\/li\u003e\n\u003cli\u003eBuffer vs claim\/regulatory shocks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClover AI boosts adherence +12%, cuts PMPM 4–6%, $420M cash fueling Medicare growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProprietary Clover Assistant drives 12% higher preventive adherence (2024) and 4–6% lower per-member medical spend in pilots; MLR improved to ~88% (2024) with Medicare segment margin ~3%; Counterpart Health targets 200+ partners by 2025 to diversify revenue; 265,000 MA members (2025) with 12% ER reduction in SDOH pilots; $420M cash (late 2025) funds AI R\u0026amp;D.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA members (2025)\u003c\/td\u003e\n\u003ctd\u003e265,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreventive adherence lift (2024)\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePer-member spend cut (pilots)\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMLR (2024)\u003c\/td\u003e\n\u003ctd\u003e~88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash (late 2025)\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Clover Health, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Clover Health SWOT matrix for rapid strategic alignment, ideal for executives needing a clear snapshot of competitive positioning and risk factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Net Losses and Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite improving medical loss ratio and member growth, Clover Health reported cumulative net losses of about $1.2 billion through FY 2024 and a GAAP net loss of $213 million in 2024, which weighs on investor sentiment.\u003c\/p\u003e\n\u003cp\u003eAchieving sustained GAAP profitability remains the core challenge as Clover balances 30%+ year-over-year revenue growth in 2024 with aggressive margin and cost controls.\u003c\/p\u003e\n\u003cp\u003eThis history of losses contributes to higher share-price volatility—CLOV swung over ±60% in 2024 vs \u0026lt;1% for large-cap healthcare insurers—raising risk for cautious investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Market Share Relative to Giants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClover Health holds about 0.2% of the Medicare Advantage market versus UnitedHealth’s ~26% and Humana’s ~14% as of 2024, leaving Clover with weaker scale, smaller marketing budgets, and fewer funds for M\u0026amp;A; this constrains its network reach and care-management investments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Sensitivity to Star Ratings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe company’s revenue depends heavily on CMS Star Ratings, which in 2024 drove roughly 8–12% of Medicare Advantage plan payments via quality bonuses; a one-star drop can cut bonuses materially and cost Clover an estimated $40–75 million annually per adjusted 2025 plan headcount scenario.\u003c\/p\u003e\n\u003cp\u003eAny decline in stars reduces competitiveness of Clover’s Medicare Advantage offerings, hurting enrollment and revenue growth; small clinical or admin lapses—missed HEDIS (quality) targets or late claims—thus carry outsized financial risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa large portion of clover health medicare advantage membership remained concentrated in new jersey pennsylvania and texas exposing the company to state-level reimbursement cuts or cost spikes a rise regional medical costs could reduce national margin materially given this concentration. diversifying into states would dilute risk but needs significant capital local provider networks reported cash equivalents at ye which may limit rapid expansion.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% membership in top 3 states (2024)\u003c\/li\u003e\n\u003cli\u003e10% regional cost increase = meaningful margin hit\u003c\/li\u003e\n\u003cli\u003eExpansion needs provider agreements + regulatory approvals\u003c\/li\u003e\n\u003cli\u003e$450m cash (YE 2024) may constrain scaling\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComplexity of Clinical Data Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe Clover Assistant depends on aggregating fragmented EHR and claims data from many providers; Clover reported integration with about 1,200 provider groups as of Q4 2024, but gaps remain.\u003c\/p\u003e\n\u003cp\u003eInconsistent data quality and interoperability (HL7\/FHIR variance) can skew real-time risk scores, reducing clinical actionability and affecting utilization trends.\u003c\/p\u003e\n\u003cp\u003eOngoing engineering spending—Clover spent $98M on R\u0026amp;D in 2024—plus provider coordination is required to fix these technical hurdles.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRelies on 1,200 provider groups (Q4 2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend $98M (2024)\u003c\/li\u003e\n\u003cli\u003eFHIR\/HL7 variability harms real-time accuracy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClover faces steep losses, tiny MA share, high star‑rating and geographic concentration risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClover carries cumulative net losses of ~ $1.2B through FY2024 and a GAAP loss of $213M in 2024, pressuring investor confidence and driving \u0026gt;±60% share volatility in 2024. Limited scale—~0.2% MA market share vs UnitedHealth ~26% and Humana ~14% (2024)—constrains marketing, M\u0026amp;A, and network reach. Star-rating dependence (8–12% of MA payments; a one‑star drop ≈ $40–75M loss) and ~60% membership concentration in top 3 states raise financial and regulatory exposure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 \/ FY2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative net losses\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGAAP net loss\u003c\/td\u003e\n\u003ctd\u003e$213M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMA market share\u003c\/td\u003e\n\u003ctd\u003e0.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 3 states share\u003c\/td\u003e\n\u003ctd\u003e~60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; equivalents\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$98M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStar-driven payment %\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOne-star impact est.\u003c\/td\u003e\n\u003ctd\u003e$40–75M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eClover Health SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full SWOT report you'll get. Purchase unlocks the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752117875065,"sku":"cloverhealth-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cloverhealth-swot-analysis.png?v=1772237927","url":"https:\/\/growthsharematrix.com\/products\/cloverhealth-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}